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Invasive candidiasis is the most common critical care-associated fungal infection with a crude 
mortality of ~40-55%. Important factors contributing to risk of invasive candidiasis in ICU include 
use of broad-spectrum antimicrobials, immunosuppressive drugs, and total parenteral nutrition 
alongside iatrogenic interventions which breach natural barriers to infection (vascular catheters, 
renal replacement therapy, Extra Corporeal Membrane Oxygenation (ECMO), surgery). This 
review discusses three key challenges in this field. The first is the shift in Candida epidemiology 
across the globe to more resistant non-albicans species, in particular, the emergence of multi-
resistant Candida glabrata and Candida auris, which pose significant treatment and infection 
control challenges in critical care. The second challenge lies in timely and appropriate initiation 
and discontinuation of antifungal therapy. Early antifungal strategies (prophylaxis, empirical and 
pre-emptive) using tools such as the Candida colonisation index, clinical prediction rules and 
fungal non-culture-based tests have been developed:  we review the evidence on implementation 
of these tools in critical care to aid clinical decision-making around the prescribing and cessation 
of antifungal therapy.  The third challenge is selection of the most appropriate antifungal to use in 
critical care patients. While guidelines exist to aid choice, this heterogenous and complex patient 
group require a more tailored approach, particularly in cases of acute kidney injury, liver 
impairment and for patients supported by Extra Corporeal Membrane Oxygenation. We highlight 
key research priorities to overcome these challenges in the future.  
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Take home message: Epidemiological shifts towards multi-resistant Candida requires enhanced 
surveillance and rigorous infection control to detect and prevent resistance emergence. The 
evidence around deployment of risk-scores and fungal non-culture-based tests in decision-
making around starting and stopping antifungals in the ICU is lacking: adequately powered multi-
site studies using a combination of tests linked to clinical and cost effectiveness outcomes are 
needed. Antifungal prescribing in special ICU populations, particularly acute kidney injury, liver 
impairment and ECMO requires a tailored approach and further PK evaluation.  
Tweet: Key ICU Candidiasis Challenges: Resistance Emergence, Biomarker-driven antifungal 



















‘Invasive candidiasis’ (IC) is an umbrella term for three clinical conditions; candidemia;  deep-
seated candidiasis; and deep-seated candidiasis with associated candidemia[1]. Cases are often 
hospital-acquired, and critically ill patients are particularly vulnerable[2], with approximately one-
third of all candidemia occurring in this setting[3]. Despite expanded access to fungicidal agents, 
IC-related outcomes remain poor, with a crude mortality of ~40-55% in Intensive Care Unit (ICU)-
focused studies over the past decade[4–7].  
The incidence of deep-seated candidiasis without concomitant candidaemia in ICU is less certain 
due to challenges in obtaining specimens for microbiological confirmation. Intra-abdominal 
candidiasis (IAC) accounts for most deep-seated cases, with ~30% occurring in critical care[8]. 
Perforation, anastomotic leaks, repeat laparotomies, necrotizing pancreatitis and abdominal 
organ transplants increase risk, therefore incidence is higher in surgical ICUs[8]. Other forms of 
deep-seated candidiasis include haematogenously disseminated disease (hepatosplenic, ocular, 
cardiac, central nervous system, bone and renal), seen more frequently with prolonged 
candidemia, and in immunosuppressed and neutropenic patients[9, 10]. Host genetics also 
influence IC susceptibility, with various single-nucleotide polymorphisms (SNPs) identified as 
increasing candidaemia risk[11].  
Figure 1. illustrates key factors contributing to development of IC in ICU. IC risk factors have 
fluctuated with advances in intensive care medicine; while there is increased use of renal 
replacement therapy, Extra Corporeal Membrane Oxygenation (ECMO), and immunosuppression 
treatments, there has been improved vascular catheter management, more judicious use of total 
parenteral nutrition (TPN) and greater emphasis on antimicrobial stewardship[12–14]. The 
collective impact of this on IC incidence is unclear. Large multi-centre studies examining IC 
incidence in ICU have been conducted over the past decade[4–7, 15–18]. Rates of candidaemia 
reported vary significantly between 3.5 – 16.5 per 1000 admissions[4, 6, 7, 16–18].  However, 
due to inter-centre variability, the fact most studies focused on candidaemia only, and some 
encompassed cases likely to represent colonization rather than IC, evaluation of IC incidence 
trends in ICU over time is challenging.  
In this narrative review, we sought to summarise key epidemiological, diagnostic and treatment 
challenges of managing IC in ICU and highlight future directions in this field. To ensure broad 
coverage of relevant literature, we undertook a MEDLINE search for English language articles 
published before 1 July 2020, using the terms “candidiasis”, “candidaemia”, “critical care”, 
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“resistance”, “biomarkers” and “antifungal”, including further relevant studies from reference lists 































Challenge 1: Changing Epidemiology and Emergence of Antifungal Resistance 
Epidemiological shifts 
There is significant geographic and demographic variation in IC[19]. C. albicans remains the 
dominant species in Europe[5–7]; in a pan-European ICU cohort study (2015-16)[6], C. albicans 
represented 57% of cases, followed by C. glabrata and C. parapsilosis.  Across India, C. tropicalis 
was the most common cause of ICU-acquired candidaemia[20], whereas C. albicans and C. 
parapsilosis predominate in Latin America[21].  The USA sees a higher proportion of non-albicans 
cases (approximately two-thirds), with increasing C. glabrata incidence[22]. Echinocandin-
resistant C. glabrata is reported; while European prevalence appears low (<1%)[23], US studies 
report a prevalence of 6-12%[24–26], with azole cross-resistance in up to one-third of isolates[27]. 
This is concerning given echinocandins are recommended first-line treatment in IC, and azoles 
the most widely used antifungals globally.  Moreover, the emergent multi-drug resistant C. auris 
has caused outbreaks on ICUs worldwide[28]. It is the 3rd most common cause of candidaemia in 
South Africa, with 88% of cases associated with ICU stays[29]. C.auris is usually fluconazole-
resistant, with variable amphotericin and echinocandin susceptibility, and pan-fungal resistance 
to all three classes reported[30].  
Reservoirs of resistance in ICU: the patient and environment 
The patient and the environment can be reservoirs of fungal resistance in ICU. Antibiotic use 
disrupts the skin and gut microbiome, increasing Candida colonization and risk of IC[31]. 
Antifungal exposure selects for less susceptible Candida species such as C. parapsilosis, C. 
krusei and C. glabrata[32] and fosters resistance; in a US study, echinocandin-resistant C. 
glabrata was associated with prior echinocandin exposure, fluconazole resistance, and prolonged 
hospitalization[26]. In Denmark, post-treatment (≥7 days) mouth swabs in candidaemic patients 
demonstrated acquired resistance to fluconazole and echinocandins in 29% and 22% of 
C.glabrata isolates respectively[33].  Specifically, reduced echinocandin penetration into the gut 
may select for the emergence of echinocandin-resistant species[33, 34].    
Resistant isolates spread between patients, and within the ICU environment, with reports of 
genotype-linked clusters of azole-resistant C. parapsilosis[35], and inter-hospital spread of azole-
resistant C. glabrata[36] in ICU. C. auris studies have described widespread contamination of 
environmental surfaces and equipment persisting for months, with patient acquisition of C. auris 
occurring after as little as 4-hours of contact[37]. The limited efficacy of commonly used 
environmental disinfectants and absence of effective skin decolonization regimens for C. auris, 
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have made transmission difficult to interrupt[38]. A UK ICU C.auris outbreak was only stemmed 
when reusable temperature probes were removed from circulation[39]. For C. auris, infection 
control measures including screening, isolation, cohorting and environmental disinfection are 
advised in Public Health guidance[40, 41]. ICU interventions for tackling fungal resistance are 
summarized in Figure 2.     
Many hospital laboratories do not identify yeasts in non-sterile specimens to species level; as a 
result, changes in ecology and resistance may go undetected. Misidentification of C. auris for 
other species, particularly C. haemulonii, when using common diagnostic platforms is 
recognized[42]. Matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF) allows 
quick, accurate identification but is not universally available.  Improving laboratory capacity for 
Candida speciation, particularly C.auris, and fungal susceptibility testing is important for 
surveillance and early detection of resistance emergence in ICU.   
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Challenge 2: When to Start and When to Stop Antifungal Therapy?  
Timely delivery of effective AFT in proven IC is crucial, as delays are associated with increased 
mortality[43]. Conversely, over-prescription may be detrimental, exposing patients to drug 
toxicities and driving resistance emergence. A cross-sectional study of French and Belgian ICUs 
demonstrated that while 7.5% of patients were prescribed systemic AFT, two-thirds subsequently 
had no evidence of IFI[44], emphasising the challenge of achieving a balance between targeted, 
timely AFT whilst avoiding excessive and unnecessary use.   
Earlier antifungal strategies have thus been developed (prophylactic, empiric, pre-emptive), 
(Table 1) although the optimal strategy in ICU remains controversial. To aid decision-making 
about stopping and starting antifungals, three key tools, for use alone or in combination, have 
been proposed: Candida colonisation assessment, clinical prediction rules, and fungal non-
culture-based tests (NCBT) (Table 2). Table 3 summaries key studies using these tools to initiate 
or discontinue AFT, however their impact on clinical practice remains hotly debated. 
Role of candida colonization and clinical prediction rules  
Candida colonization is considered a pre-requisite for the development of IC (Fig.1)[62]; those 
with a higher Candida Colonization Index (CCI) are at greater risk[45]. However, although the 
proportion of ICU patients colonized with Candida increases over time (~50-80%), only 5-30% will 
develop IC[63]. While studies have proposed colonization can be used to guide prophylaxis and 
reduce IC[64–66], they have not shown a mortality benefit. A study found colonization-triggered 
caspofungin or azole use changed the ICU fungal ecology (increased C. glabrata), without 
reducing IC-associated mortality or incidence[67]. Hence, the moderate positive predictive value 
(PPV) of this approach (~66% for CCI[45]) could lead to excessive antifungal use that is neither 
appropriate or cost-effective.     
To improve the PPV, clinical prediction rules, incorporating host factors with or without Candida 
colonization, have been established. The UK FIRE Study reviewed ~60,000 ICU admissions and 
evaluated risk models for predicting IC. However, IC incidence was lower than expected (0.6%), 
and analysis suggested a strategy of no risk-assessment or AFT prophylaxis was the most cost-
effective [68].   
RCTs have evaluated the impact of clinical prediction rules triggering early AFT on IC incidence 
and mortality in ICU. The MSG-01 trial[57] (n=219) randomized to caspofungin prophylaxis or 
placebo based on the Ostrosky-Zeichner Clinical Prediction Rule, demonstrating a non-significant 
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reduction in IC (9.8% vs 16.7%, p=0.14) and no difference in all-cause mortality (16.7% vs 14.3%, 
p=0.78).  
The similarly-sized INTENSE trial[58] (n=241) randomized ICU patients with intra-abdominal 
infection requiring emergency surgery to ‘pre-emptive’ micafungin or placebo. Given prescribing 
was not based on NCBTs or radiology, current definitions would consider this an antifungal 
prophylaxis trial.  There was no reduction in IC incidence (micafungin 11.1% vs placebo 8.9%). 
AFT was possibly initiated too late (max. 120-hours post-surgery) given many developed IC early 
in their admission. No details around source control were presented (e.g. drainage of 
collections/second laparotomies), which may play a more significant role than early AFT in 
patients with a surgical abdominal focus.  
Both trials suggest early AFT based on risk factors alone does not reduce IC incidence or impact 
mortality. However, they also illustrate the challenges of powering studies adequately: in the 
MSG-01 trial, IC incidence in the control group was lower than expected, and the INTENSE trial 
highlighted the importance of selecting the right at-risk group and timepoint for intervention.  
Empirical antifungal therapy in ICU  
Given signs and symptoms of IC are non-specific, overlapping with many other infectious and 
non-infectious aetiologies, empirical AFT to cover the possibility of fungal infection in the septic 
ICU patient is common practice. A major factor driving empirical therapy are limitations of 
conventional culture-based methods. Although gold-standard for diagnosing IC, blood culture 
(BC) sensitivity is suboptimal (~75% in bloodstream infection, ~5-20% in abdominal 
candidiasis)[1, 69],  sterile site sampling (e.g. abdominal pus)  often difficult, and time-to-culture-
positivity prolonged (2-3 days)[1].  
No survival benefit of early AFT in non-neutropenic ICU patients was demonstrated in a 2016 
meta-analysis (>2300 patients from 22 RCTs)[70], although criteria triggering antifungal 
prescribing in the analyzed studies were very heterogenous. Subsequently, the EMPIRICUS 
trial[59] (n=261) randomized ventilated patients with evidence of ICU-acquired sepsis, Candida 
colonization, and multi-organ failure to empirical micafungin or placebo.  No improvement in 28-
day fungal-free survival was demonstrated (68% vs 60.2%, p=0.18), despite significant reduction 
in proven IC in the micafungin arm (3% vs 12%, p=0.008). Subgroup analysis suggested a trend 
towards better survival in those with SOFA score >8 (HR, 1.69 [95% CI, 0.96-2.94], p=0.07); 
Demonstrating survival benefit in ICU patient groups, often with multiple co-morbidities and high 
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baseline mortality, requires much larger trials to achieve adequate power. Identifying the subset 
of ICU patients who could benefit from early AFT remains a key challenge.  
Guidelines do not address de-escalation or discontinuation of empirical therapy for suspected 
infection in the absence of microbiological confirmation. In a post-hoc analysis (n=647) of the 
observational ARMCAND2 study including patients with suspected(57%)  or proven IC(43%), de-
escalation (defined as either switch to azole or antifungal discontinuation by day 5) only occurred 
in 22% (n=142; 96 switched; 48 stopped), of which half had no microbiological evidence of IC[71]. 
De-escalation was associated with shorter total AFT duration, with no negative impact on mortality 
or length of ICU stay despite similar illness severity scores between those who did and did not 
de-escalate. A smaller observational study had similar findings[72]. Nevertheless, the low 
proportion switched or stopped highlights barriers to de-escalation in practice. This includes 
reluctance to modify empirical treatment in unstable patients with uncertain diagnoses, alongside 
a desire to use a fungicidal, well-tolerated agent to cover the possibility of azole-resistant Candida. 
Yet, for patients on empirical therapy where the clinical picture suggests low IC-risk and BC are 
negative, discontinuing AFT appears a reasonable option and could be beneficial in preventing 
resistance emergence. For those where likelihood of IC is deemed moderate-to-high, non-culture-
based diagnostics may have a role in informing decisions. 
Role of non-culture-based tests  
Non-culture-based tests (NCBTs) have been developed in attempt to overcome the shortfalls of 
culture-based fungal diagnostics, given their quick turn-around-time, the potential for earlier IC 
detection and given they may remain positive for longer while on AFT[1]. They include 1,3-β-d-
glucan (BDG), T2 magnetic resonance Candida assay (T2Candida), Multiplex candida real-time 
PCR, and the detection of mannan antigen (MAg) and anti-mannan IgG antibodies (Anti-Mn) 
(Table 2).  Potential roles for NCBTs include aiding clinical decision-making to guide; 1) the 
initiation of pre-emptive AFT; 2) the discontinuation or withholding of empirical AFT; 3) monitoring 
clinical improvement in patients with IC. 
NCBTs have been described as “Bayesian”[69]; i.e. they do not deliver a definitive result, but 
assess the likelihood of infection. IC prevalence varies between ICUs due to differences in case-
mix and interventions. With variation in the pre-test likelihood, the negative predictive value (NPV) 
and PPV of NCBTs changes; in higher-risk patients and settings (e.g. surgical ICU) the PPV will 
rise and the NPV will decrease, and vice-versa[69]. Hence, as recently outlined in Mycoses Study 
Group recommendations, NCBTs must be requested and interpreted in the context of the pre-test 
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likelihood of IC[73]; they suggest that the clinical value of NCBTs is limited when this figure is less 
than 10%.   
Non-culture-based tests to trigger antifungal initiation   
The ideal NCBT for guiding early antifungal initiation needs a high sensitivity to identify IC, but 
reasonable specificity to avoid over-prescribing. The most widely used NCBT, BDG, has 
moderate specificity (~60-85%[48–50]), marred by false-positivity which may occur due to 
haemodialysis, blood product administration, high-burden Candida colonisation, and disturbed 
GI-mucosa; all common in ICU. This may result in antifungal overuse. Establishing diagnostic cut-
off values which optimise test performance in ICU is crucial. BDG specificity improves with 
consecutive sampling and increasing the ‘positive’ cut-off value to ≥250 pg/ml (instead of 
80 pg/ml[74]) which in one study increased specificity to 87% but reduced sensitivity to 52%[75]. 
NCBT combinations may also improve specificity; a positive BDG (≥80 pg/ml) alongside a 
negative PCT (<2 ng/ml) had a 96% PPV for candidaemia, when distinguishing IC from 
bacteraemia in one study[76]. Additionally, a highly-positive BDG (>259 pg/ml) alongside a 
positive CAGTA better distinguished IC from candida colonisation in patients with severe 
gastrointestinal conditions, compared to either used alone[75]. A prospective Danish study 
(n=126) in ICU patients at high-risk of IC (particularly IAC) found a combination of T2Candida and 
BC compared to MAg and BC, or BC alone had a the greatest specificity (64%/53%/29% 
respectively), and a sensitivity of >95%, for diagnosing proven/likely IC[77]. Additionally, a 
retrospective study assessing NCBTs performance for IAC (n=48) found the sensitivity/specificity 
for T2Candida was 33%/93% and BDG 83%/67%; however concordant positive results diagnosed 
IAC in 100% of cases, and concordant negative results excluded IAC in 90% of cases, suggesting 
combinations would be more useful clinically[78].  
To date, few prospective studies have examined the impact of NCBT-driven pre-emptive AFT on 
outcomes[79]. A small pilot RCT (n=64) administered pre-emptive anidulafungin to ICU patients 
with a BDG ≥60 pg/ml[56] during twice-weekly surveillance; while it demonstrated feasibility, 
enrolment difficulties meant it was not powered to assess a difference in IC or survival. In a sub-
group analysis of the EMPIRICUS study, fungal-free survival was not significantly different in 
those with an elevated BDG who received micafungin versus placebo (BDG >80 [HR 1.41, 95% 
CI 0.85-2.33], BDG >200 [HR 1.51, 95% CI 0.47-5.00]), but the trend was in the direction of the 
micafungin arm[59].  
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Current evidence is not robust enough to support the use of NCBTs alone to trigger AFT. The 
moderate specificity of BDG hinders its use, but combination with other NCBTs, optimising ‘cut-
off’ values, and directing testing to ‘high risk’ patients using Candida risk scores, make it a more 
valuable tool. NCBT-driven pre-emptive therapy using NCBT combinations which maximise test 
performance (T2Candida plus BDG) alongside culture is the most promising early AFT strategy 
which needs to be examined robustly in randomised multi-centre clinical trials. Outcomes should 
include IC, mortality, AFT consumption and cost-effectiveness, so benefits and risks of such a 
strategy can be holistically assessed. We eagerly await the results of the CandiSep trial 
(NCT02734550) comparing clinical outcomes of a BDG-driven versus culture-driven approach to 
AFT prescribing in septic ICU patients.  
Non-culture-based tests to aid antifungal discontinuation  
NCBTs with a high NPV may be better used to guide discontinuation or preventing initiation of 
AFT. A trial (n=109) randomized patients with evidence of infection who fulfilled IC-risk criteria to 
14-days’ empirical AFT or a NCBT-driven strategy, whereby AFT was stopped if BDG, MAg, Anti-
Mn, and BC were negative[61]. Unsurprisingly, given comparison was to a 14-day standard, AFT 
duration was shorter in the NCBT arm, but importantly there was no deleterious impact on 
mortality or development of IC. A further study (n=85) prescribed empirical AFT to patients with 
risk factors and signs of infection[60]; based on negative BC and serial negative BDGs, AFT was 
safely discontinued in 21/85 by day 4 and none developed candidaemia upon follow-up. Other 
retrospective studies demonstrated similar findings[80, 81]. An ICU study assessing utility of BDG 
for therapeutic decision-making found that although introduced to target patients ‘high-risk’ of IC, 
in practice only 26% of patients in whom it was used were in this category[82]. Results influenced 
AFT prescribing in over half of cases, deemed appropriate in three quarters and inappropriate in 
a quarter of cases (AFT continued/started with no subsequent evidence of IFI). Thus 
paradoxically, in real-world deployment of ICU BDG testing, any reductions in antifungal 
consumption gained through earlier stopping of inappropriate therapy based on the test’s good 
NPV may be outweighed by an excess in prescribing due to the test’s poor PPV when used in an 
unselected population. Studies so far have been too small to assess the safety and clinical 
effectiveness of NCBT-driven AFT discontinuation algorithms. Multi-site studies comprising a 
range of low-to-high IC prevalence settings are needed for results to be generalisable.  
In summary, whilst NCBT results interpreted in context remain a useful adjunct in stewardship, to 
date there is insufficient evidence to support antifungal discontinuation based on negative 
NCBT[48, 83]. The A-STOP trial (ISRCTN43895480), a large multi-site (35 hospital) UK 
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diagnostic accuracy study prospectively assessing which NCBT (or combination thereof) can best 
rule-out IC and facilitate AFT discontinuation in ICU patients, holds promise of delivering on this. 
Non-Culture-Based Tests for Monitoring  
Clinical response markers for monitoring and prognostication in IC are lacking. BC clearance of 
fungi is often used as a proxy for treatment effectiveness, however this is less-than-ideal given 
their suboptimal sensitivity, particularly in deep-seated candidiasis.  
Studies in ICU[77] and mixed ward/ICUs[84], found T2Candida remained detectable for longer 
than BC in candidaemia; in the latter study 7.5% (4/31) had a positive surveillance BC, yet 41.9% 
(13/31) had a positive surveillance T2Candida. Hence, time-to-negative result with T2Candida 
was significantly longer, perhaps unsurprising given T2Candida also detects non-viable Candida 
cells. To assess its clinical relevance, larger studies correlating persistent T2Candida positivity 
with clinical outcomes are needed. While studies have examined BDG kinetics for monitoring 
treatment response in IC[85–87], few have done so in an ICU-specific population[88, 89]. In 
heterogenous patient groups, serial BDG decline has been associated with successful therapy, 
with a slower decrease in patients with deep-seated candidiasis[85, 86], and persistently negative 
BDGs in candidaemic patients are associated with a lower 30-day mortality[90, 91].  However, in 
ICU patients with intra-abdominal candidiasis[88] and candididaemia[89] BDG was slow to clear 
from circulation and remained positive beyond clinical resolution of infection. Hence, while the 
trajectory of decline, or persistent negativity may have some monitoring use, there is little 
evidence to support that transition from a positive to negative BDG is valuable in assessing 
treatment response and currently no evidence that it can be used to guide AFT duration.   
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Challenge 3: Choosing the Optimal Antifungal Drug for the ICU Patient  
 
The antifungal armamentarium is limited, with just four classes of drugs available for treatment of 
IC; azoles (fluconazole, voriconazole); echinocandins (caspofungin, anidulafungin, micafungin); 
polyenes (amphotericin B); and the pyrimidine analogue, flucytosine. Drug development is 
progressing, with several new agents undergoing trials (e.g. Ibrexafungerp, fosmanogepix, 
rezafungin)[92].  
Several guidelines aid the appropriate selection of an antifungal[93, 94]. Echinocandins are 
recommended first-line  treatment of proven[93, 94] and suspected[93] IC in non-neutropenic 
critically ill adults, due to their broader-spectrum compared to fluconazole, fungicidal activity, 
excellent tolerability and minimal drug interactions. In the only comparative RCT, anidulafungin 
was found to be non-inferior to fluconazole for the treatment of IC (global response 73.2% versus 
61.1%, 95% CI, −1.1 to 25.3)[95]. A post-hoc subgroup analysis in ICU patients demonstrated 
significantly better response rates for those receiving an echinocandin (70.8% versus 54.1%, 
p=0.03), although this did not translate to a reduction in 28-day mortality (20.2% versus 24.3% P 
=0.57)[96]. Other observational studies comparing mortality between those initiated on 
fluconazole or echinocandins, showed either no difference[97–99], or favoured 
echinocandins[100, 101]. However, adjusting for the multiple confounders influencing outcome in 
ICU in non-randomised studies is difficult. A recent large RCT failed to demonstrate non-inferiority 
of the newest triazole, isavuconazole, when compared to caspofungin for IC (end-of-IV-therapy 
treatment response, 60.3% versus 70.1%, 95%CI -19.9– -1.8), consistent regardless of illness 
severity[102]. There is no evidence to suggest a difference in efficacy or mortality with 
Amphotericin B compared to azoles and echinocandins[103]. Given the higher cost and 
association with greater toxicity, amphotericin B in IC treatment is usually reserved for situations 
with no suitable alternatives eg. MDR Candida, for drug-penetration.  
In candidaemia, de-escalation from echinocandins to fluconazole for azole-susceptible isolates, 
when repeat BCs are negative and the patient is clinically stable is recommended within 5-7 days 
in IDSA[93], and at 10-days in ESCMID guidelines[94].  A number of studies, (albeit not RCTs) 
have demonstrated the safety of this approach at day 5 in proven IC[71, 100, 104] with no impact 
on clinical outcomes. The ESGCIP taskforce recently recommended considering de-escalation at 




Antifungal drugs in special ICU populations  
Alongside guidelines, patient-specific factors need to be considered when choosing the most 
appropriate drug, dose and duration for different clinical scenarios[106], summarised in table 4.  
Acute kidney injury (AKI) is common in ICU, sometimes requiring continuous renal replacement 
therapy (CRRT) which can significantly affect antifungal PK/PD. The kidneys excrete 60-80% of 
fluconazole unchanged[107]; dose reduction in AKI is thus required due to delayed elimination. 
Conversely, high elimination is seen with CRRT due to low protein-binding and high water 
solubility, therefore increased fluconazole doses are advised[107]. For voriconazole, no renal or 
CRRT dose adjustment is required but frequent TDM is needed. Given the voriconazole IV solvent 
vehicle can accumulate in moderate-to-severe renal impairment, oral over IV therapy is 
recommended[107]. Amphotericin B, particularly the deoxycholate formulation, can be associated 
with nephrotoxicity and should be avoided in renal impairment if suitable alternatives are 
available. CRRT dose adjustment is not required. Echinocandins are highly protein-bound with 
minimal renal excretion, therefore no dose adjustment is required in renal failure, and CRRT has 
no clinically significant effect on drug removal[108], making them an optimal choice.  
Chronic and acute liver failure is frequently seen in ICU patients. Drug-induced liver injury (DILI) 
is a risk with all azoles, therefore caution is required in pre-existing moderate or severe liver 
disease and alternatives considered. No dose adjustment is required for amphotericin [109]. 
Anidulafungin is the only echinocandin eliminated through extrahepatic metabolism[110] and 
therefore often the preferred agent in hepatic impairment.  
ECMO is increasingly used for cardiorespiratory support in ICU; altered antifungal PK/PD may 
occur due to drug sequestration, increased volume of distribution, and drug clearance changes 
while on the ECMO circuit, but data are scarce[111]. Micafungin extraction by ECMO was 
demonstrated in an ex-vivo study[112], however there are conflicting data with caspofungin[113, 
114], the latter study demonstrating adequate levels at usual doses. Satisfactory liposomal 
amphotericin B levels at standard dosing on ECMO are reported[115], while others administering 
higher doses (10mg/kg/day) found a ~50% reduction in Cmax[116]. Due to increased volume 
distribution, larger fluconazole loading doses were required in children, however adult data are 
lacking[111, 117]. Voriconazole sequestration is reported, although the degree of sequestration 
changes with time, possibly due to saturation of ECMO circuit binding sites[114]. Hence frequent 
azole TDM is crucial yet rarely available in real-time, highlighting a pressing need for development 
of point-of-care antifungal TDM in ICU patients. Given expanding ICU ECMO use and its 
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association with higher IFI risk, further antifungal PK/PD studies are needed as current data is 
insufficient to adequately inform antifungal ECMO guidelines.   
CONCLUSION 
The diagnosis and management of IC poses many challenges in critical care; numerous 
unanswered questions remain as research priorities (Table 5). Improved identification of at-risk 
patients and the widening spectrum of diagnostics and therapeutics available for IC are promising. 
Personalized approaches to drug dosing and monitoring treatment response are needed.  The 
key knowledge gap remaining is how tools such as risk scores and NCBTs can best be 
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